Science AI Journal
Medicine · Research topic

Open research questions in Antiplatelet Therapy and Cardiovascular Diseases

112 unresolved questions extracted from the limitations and future-work sections of 452 Antiplatelet Therapy and Cardiovascular Diseases papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Clopidogrel-based dual antiplatelet therapy is substantially limited by the CYP2C19 gene polymorphism. There is a need for an effective strategy for preventing END in HR-NICE patients.

    Low-dose ticagrelor combined with aspirin for preventing early neurological deterioration in patients with high-risk non-disabling ischemic cerebrovascular events: a multicenter, prospective, randomized, open-label, clinical trial · 2026 · DOI

  • Based on observational data, - Potential selection bias from excluding participants with missing data, - Limited generalizability to other populations

    Lp(a), platelet count, aspirin and cardiovascular outcome: a prospective cohort analysis · 2026 · DOI

  • Investigation of the biological mechanisms underlying the association between Lp(a) and platelet count, - Examination of the effectiveness of aspirin in reducing MACE risk in participants with elevated Lp(a) and increased platelet count, - Study of the potential benefits of targeting Lp(a) and platelet count in cardiovascular disease prevention

    Lp(a), platelet count, aspirin and cardiovascular outcome: a prospective cohort analysis · 2026 · DOI

  • Abstract Background Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular diseases (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain.

    Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial · 2026 · DOI

  • Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials.

    Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial · 2026 · DOI

  • Background Data are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS).

    Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock · 2024 · DOI

  • This evidence calls for expanded research to validate and extend these preliminary observations, emphasizing the importance of further investigation into cangrelor's applications in complex patient care scenarios.

    Navigating P2Y12 inhibition in the labyrinth of cardio-oncology care: cangrelor bridging in patients with cancer · 2024 · DOI

  • Nevertheless, the impact of this strategy on outcomes based on sex remains unclear.

    Sex-based outcomes on unguided de-escalation from ticagrelor to clopidogrel in stabilized patients with acute myocardial infarction undergoing percutaneous coronary intervention: a post-hoc analysis of the TALOS-AMI · 2024 · DOI

  • Specific to elective CABG, evidence is mixed, with some data indicating no significant difference in thrombotic or bleeding complications whether aspirin is continued or withheld preoperatively.

    To be or not to be on: aspirin and coronary artery bypass graft surgery · 2024 · DOI

  • The precarious balance between preventing ischemia and provoking bleeding places clinicians in a persistent therapeutic dilemma. Current guidelines and risk stratification tools have limitations. There is a need for a more integrated approach to managing antithrombotic therapy.

    Toward an integrated risk paradigm: personalizing antithrombotic therapy for coronary heart disease with gastrointestinal bleeding · 2026 · DOI

  • Advancing the proposed approach will depend on collaborative efforts across academic, clinical, and healthcare-administrative domains. Priorities should include the development of integrated risk-assessment tools and prospective research focused on personalized treatment strategies.

    Toward an integrated risk paradigm: personalizing antithrombotic therapy for coronary heart disease with gastrointestinal bleeding · 2026 · DOI

  • Indication bias may be present, given that patients in the AP group had higher prevalences of coronary artery disease and other high-risk features. The study has a relatively small sample size. The role of antiplatelet therapy in primary prevention among at-risk populations remains poorly defined.

    A Retrospective Study of 518 Kidney Transplant Recipients to Evaluate the Association of Antiplatelet Therapy With Long-Term Cardiovascular Events and All-Cause Mortality · 2026 · DOI

  • The role of antiplatelet therapy in primary prevention among at-risk populations remains poorly defined. There is a need for further research to fully understand the association of antiplatelet therapy with long-term cardiovascular events and all-cause mortality in kidney transplant recipients.

    A Retrospective Study of 518 Kidney Transplant Recipients to Evaluate the Association of Antiplatelet Therapy With Long-Term Cardiovascular Events and All-Cause Mortality · 2026 · DOI

  • The optimal duration of DAPT after coronary artery bypass grafting remains unclear. There is a need for individualised post-CABG antiplatelet strategies.

    Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial · 2026 · DOI

  • international largely guide CABG surgical techniques, perioperative management, and postoperative antiplatelet strategies, the predominance of enrolment from one centre may still limit the generalisability to other healthcare settings with differing patient characteristics, surgical practices, and perioperative management patterns. Sixthly, the trial was powered for the primary endpoint of SVG patency and may have been underpowered to detect differences in secondary clinical endpoints, particularly MACCE. These findings should therefore be interpreted as exploratory. Seventhly, our trial was not designed to identify patients for whom aspirin monotherapy was preferable; comparing a shortened DAPT strategy with aspirin alone represented a logical next step. Eighthly, although the non-inferiority margin was determined based on statistical preservation of effect considerations and expert consensus, it was not informed by empirical data on patient preference or established thresholds for minimal clinically important differences. Therefore, the selected margin may not represent a validated clinical threshold. Ninthly, the data and safety monitoring board review was conducted every six months. While no major safety concerns were identified during the trial, we acknowledge that a more frequent monitoring schedule would have aligned better with evolving standards for high risk surgical interventions, and a more geographically diverse and multi-institutional committee structure would further enhance independence. Tenthly, our security protocol relied on two stage authentication involving a mandatory virtual private network gateway followed by application level credentials. Although this security measure provides robust network isolation, we acknowledge that it does not constitute formal two factor authentication as defined by modern cybersecurity standards, representing a technical limitation. Eleventhly, a higher rate of infection events was observed in the 12 month DAPT group. However, our trial did not systematically collect data on baseline infection risk factors, duration of antibiotic treatment, or details of prophylactic antibiotic use, which limited our ability to adjust for these factors.

    Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial · 2026 · DOI

  • There is a need for individualized treatment strategies based on ischemic and bleeding risk in patients with chronic coronary syndrome. The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention is uncertain.

    Current Strategies for Optimizing Antithrombotic Therapy in Patients with Chronic Coronary Syndrome: A Dynamic Approach · 2026 · DOI

  • Limited compliance with guidance for duration of clopidogrel. Variation in compliance across the Veterans Integrated Service Network (VISN), VAMC, and surgeons.

    Compliance with the Veterans Health Administration’s Pharmacy Benefit Management guidance for duration of clopidogrel following peripheral vascular interventions: a retrospective cohort study · 2026 · DOI

  • Further study of the factors associated with compliance. Examination of the impact of compliance on patient outcomes. Development of strategies to improve compliance.

    Compliance with the Veterans Health Administration’s Pharmacy Benefit Management guidance for duration of clopidogrel following peripheral vascular interventions: a retrospective cohort study · 2026 · DOI

  • The study had a limited sample size, with 3,708 patients included. The study had missing data for some variables, with 437 patients excluded from multivariate analyses.

    Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention · 2026 · DOI

  • The optimal antithrombotic strategy in patients with acute coronary syndrome undergoing percutaneous coronary intervention and treated with direct oral anticoagulants is unclear. The comparison of ticagrelor and clopidogrel in these patients has not been well studied.

    Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention · 2026 · DOI

  • The current guidelines do not recommend low-dose aspirin for routine primary prevention in older adults due to bleeding risks outweighing vascular benefits. There is a need to identify subgroups of older adults who may benefit from aspirin for primary prevention of ischemic stroke.

    Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke · 2026 · DOI

  • The use of preoperative DAPT in CEA patients is controversial due to conflicting findings on its benefits and risks. There is a need to clarify the risks and benefits of preoperative DAPT in CEA patients.

    Impact of preoperative dual antiplatelet therapy vs. aspirin monotherapy on perioperative outcomes in carotid endarterectomy patients: a retrospective cohort study · 2026 · DOI

  • The number of studies in each subgroup was limited - The absolute incidence of hard clinical endpoints was low - The study had limited statistical power to test for interactions between subgroups and treatment

    Time- and risk-dependent effects of dual antiplatelet therapy targeting the P2Y12 receptor after CABG: A network meta-analysis of graft permeability and clinical outcomes · 2026 · DOI

  • The optimal strategy for intensified antithrombotic therapy after CABG remains unclear - There is a need for further studies to investigate the effects of dual antiplatelet therapy on graft permeability and clinical outcomes

    Time- and risk-dependent effects of dual antiplatelet therapy targeting the P2Y12 receptor after CABG: A network meta-analysis of graft permeability and clinical outcomes · 2026 · DOI

  • The efficacy of clopidogrel varies considerably due to the influence of both CYP2C19 polymorphisms and clinical factors - There is a need to identify patients who may not respond to clopidogrel

    ABCD-GENE Score Stratifying Risk-Benefit Profile of Clopidogrel-Aspirin Therapy in Ischemic Stroke Within 24–72 Hours · 2026 · DOI

Most-cited papers in Antiplatelet Therapy and Cardiovascular Diseases

Most recent work

Find a gap in your own Antiplatelet Therapy and Cardiovascular Diseases sub-topic

This page shows what the Antiplatelet Therapy and Cardiovascular Diseases literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
112 open questions have been extracted from the limitations and future-work passages of 452 Antiplatelet Therapy and Cardiovascular Diseases papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.